Literature DB >> 9523662

Prediction of pathological stage and clinical outcome in prostate cancer: an improved pre-operative model incorporating biopsy-determined intraductal carcinoma.

R J Cohen1, W C Chan, S G Edgar, E Robinson, N Dodd, S Hoscek, I P Mundy.   

Abstract

OBJECTIVE: To relate the predictive value of serum prostate specific antigen (PSA) levels, histological grade and intraductal carcinoma (IDC-P, a possible marker of poor prognosis) to pathological stage and subsequent clinical outcome, and thus derive an improved predictive model to aid the decision to initiate potentially curative therapy in localized prostate cancer.
MATERIALS AND METHODS: Fifty-nine radical prostatectomy specimens were histologically graded, allocated a pathological stage and the tumour volume determined by image analysis. Pre-operative (needle biopsy) tumour grade, the presence or absence of IDC-P, and serum PSA levels were correlated with the pathological stage. This was used to define the sequence and values that would be incorporated into a predictive model for pathological stage and clinical outcome.
RESULTS: There were close correlations between cancer volume and tumour grade (P = 0.004) and between cancer volume and serum PSA level (P = 0.003). However, in tumours with IDC-P, serum PSA level did not correlate with tumour volume of IDC-P (P > 0.9). IDC-P was an independent variable that significantly improved the prediction of pathological stage and tumour volume, and furthermore, was closely related to (r = 0.53, P = 0.001) and accurately predicted treatment failure.
CONCLUSION: The model which best predicted pathological stage and clinical outcome involved first identifying those cancers with IDC-P as having the poorest outcome. Cancers without IDC-P were then separated into low- and high-risk groups on the basis of serum PSA levels below and above 10 ng/mL, and those in the high-risk group further stratified using Gleason grading. Furthermore, the use of a sequential consideration of pre-operative variables including IDC-P allowed cases to be grouped which, after radical surgery, closely correlated with clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523662     DOI: 10.1046/j.1464-410x.1998.00530.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  15 in total

1.  Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.

Authors:  Ekaterina Olkhov-Mitsel; Farshid Siadat; Ken Kron; Liyang Liu; Andrea J Savio; John Trachtenberg; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  Oncol Lett       Date:  2017-05-09       Impact factor: 2.967

Review 2.  Intraductal carcinoma of prostate: a comprehensive and concise review.

Authors:  Jordan A Roberts; Ming Zhou; Yong Wook Park; Yong Wok Park; Jae Y Ro
Journal:  Korean J Pathol       Date:  2013-08-26

3.  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

Authors:  Catherine O'Brien; Lawrence D True; Celestia S Higano; Brooks L S Rademacher; Mark Garzotto; Tomasz M Beer
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

Review 4.  My approach to intraductal lesions of the prostate gland.

Authors:  M Pickup; T H Van der Kwast
Journal:  J Clin Pathol       Date:  2007-01-19       Impact factor: 3.411

5.  Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.

Authors:  Carlos L Morais; Jeong S Han; Jennifer Gordetsky; Michael S Nagar; Ann E Anderson; Stephen Lee; Jessica L Hicks; Ming Zhou; Cristina Magi-Galluzzi; Rajal B Shah; Jonathan I Epstein; Angelo M De Marzo; Tamara L Lotan
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

6.  Alternative performance measures for prediction models.

Authors:  Yun-Chun Wu; Wen-Chung Lee
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 7.  Intraductal Carcinoma of the Prostate Gland: Recent Advances.

Authors:  Mukul K Divatia; Jae Y Ro
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

Review 8.  Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review.

Authors:  A Marije Hoogland; Charlotte F Kweldam; Geert J L H van Leenders
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

9.  Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer.

Authors:  A Marije Hoogland; René Böttcher; Esther Verhoef; Guido Jenster; Geert J L H van Leenders
Journal:  Oncotarget       Date:  2016-06-21

10.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.